开云app官网登录入口网页版-官方正版

#Secukinumab#

16篇内容 | 1122人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1488565, encodeId=dec11488565c4, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=Br J Dermatol：在体重≥90 kg的中重度斑块状银屑病患者中Secukinumab 的疗效如何？, objectType=article, longId=732994, objectId=5689e3299402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5689e3299402, replyNumber=0, likeNumber=60, createdTime=2022-07-23, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5689e3299402, moduleTitle=Br J Dermatol：在体重≥90 kg的中重度斑块状银屑病患者中Secukinumab 的疗效如何？, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5689e3299402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488564, encodeId=b58a14885647c, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=Rheumatol Ther：Secukinumab治疗银屑病关节炎或强直性脊柱炎患者的长期研究, objectType=article, longId=730107, objectId=dbcee30107b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbcee30107b2, replyNumber=0, likeNumber=72, createdTime=2022-06-22, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbcee30107b2, moduleTitle=Rheumatol Ther：Secukinumab治疗银屑病关节炎或强直性脊柱炎患者的长期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=dbcee30107b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488563, encodeId=3d7714885635a, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=JAMA Dermatol：Secukinumab治疗与银屑病患者皮肌炎恶化的关系, objectType=article, longId=300098, objectId=955d30009866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=955d30009866, replyNumber=0, likeNumber=73, createdTime=2022-03-06, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=955d30009866, moduleTitle=JAMA Dermatol：Secukinumab治疗与银屑病患者皮肌炎恶化的关系, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=955d30009866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488562, encodeId=b6f1148856234, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=Clin Pharmacol Ther:Secukinumab治疗银屑病的创新儿科开发之路, objectType=article, longId=294274, objectId=fe2d2942e48c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe2d2942e48c, replyNumber=0, likeNumber=60, createdTime=2022-01-20, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe2d2942e48c, moduleTitle=Clin Pharmacol Ther:Secukinumab治疗银屑病的创新儿科开发之路, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=fe2d2942e48c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488561, encodeId=3d3e1488561f3, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性, objectType=article, longId=218429, objectId=869b2184298f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=869b2184298f, replyNumber=0, likeNumber=70, createdTime=2021-10-13, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=869b2184298f, moduleTitle=NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=869b2184298f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488560, encodeId=97bd14885609e, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著, objectType=article, longId=195876, objectId=4d741958e69f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d741958e69f, replyNumber=0, likeNumber=68, createdTime=2020-06-16, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d741958e69f, moduleTitle=SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4d741958e69f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488559, encodeId=fb77148855923, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=Lancet：Secukinumab vs adalimumab用于治疗银屑病关节炎, objectType=article, longId=193804, objectId=db0219380405, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db0219380405, replyNumber=0, likeNumber=62, createdTime=2020-05-10, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db0219380405, moduleTitle=Lancet：Secukinumab vs adalimumab用于治疗银屑病关节炎, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=db0219380405)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488558, encodeId=651814885585b, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=Lancet：Guselkumab vs Secukinumab用于中重度银屑病, objectType=article, longId=177645, objectId=b4301e764526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4301e764526, replyNumber=0, likeNumber=58, createdTime=2019-08-16, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4301e764526, moduleTitle=Lancet：Guselkumab vs Secukinumab用于中重度银屑病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=b4301e764526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488557, encodeId=9a02148855ee8, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=J Am Acad Dermatol：Secukinumab对中度到重度的头皮银屑病患者有效且安全, objectType=article, longId=108672, objectId=2df31086e294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2df31086e294, replyNumber=0, likeNumber=96, createdTime=2017-08-14, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2df31086e294, moduleTitle=J Am Acad Dermatol：Secukinumab对中度到重度的头皮银屑病患者有效且安全, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2df31086e294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488556, encodeId=0685148855680, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=Arthritis Rheumatol：苏金单抗Secukinumab治疗活动性类风湿关节炎研究, objectType=article, longId=100632, objectId=0b3410063247, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b3410063247, replyNumber=0, likeNumber=0, createdTime=2017-06-05, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b3410063247, moduleTitle=Arthritis Rheumatol：苏金单抗Secukinumab治疗活动性类风湿关节炎研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0b3410063247)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488555, encodeId=68b31488555f2, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=2016NICE技术评估指南：Secukinumab用于非甾体类抗炎药或TNF抑制剂治疗后强直性脊柱炎活动期的治疗（TA407）发布, objectType=article, longId=81136, objectId=2d358113649, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d358113649, replyNumber=0, likeNumber=63, createdTime=2016-10-28, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d358113649, moduleTitle=2016NICE技术评估指南：Secukinumab用于非甾体类抗炎药或TNF抑制剂治疗后强直性脊柱炎活动期的治疗（TA407）发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2d358113649)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488554, encodeId=9c981488554b9, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=2015NICE技术评估指南：secukinumab治疗中重度斑块型银屑病（TA350）发布, objectType=article, longId=81033, objectId=f6618103358, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6618103358, replyNumber=0, likeNumber=49, createdTime=2016-10-27, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6618103358, moduleTitle=2015NICE技术评估指南：secukinumab治疗中重度斑块型银屑病（TA350）发布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=f6618103358)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488553, encodeId=f9541488553bf, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=NEJM：Secukinumab可显著改善活动期强直性脊柱炎症状, objectType=article, longId=61098, objectId=a8806109886, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a8806109886, replyNumber=0, likeNumber=73, createdTime=2015-12-25, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a8806109886, moduleTitle=NEJM：Secukinumab可显著改善活动期强直性脊柱炎症状, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a8806109886)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488552, encodeId=3d3f148855295, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=诺华单抗secukinumab强直性脊柱炎III期临床大获成功, objectType=article, longId=41756, objectId=a38e41e563a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a38e41e563a, replyNumber=0, likeNumber=72, createdTime=2014-10-29, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a38e41e563a, moduleTitle=诺华单抗secukinumab强直性脊柱炎III期临床大获成功, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a38e41e563a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488551, encodeId=235f148855150, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=华公司抗炎症药物secukinumab治疗银屑性关节炎取得重大突破, objectType=article, longId=40760, objectId=84da40e602c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84da40e602c, replyNumber=0, likeNumber=57, createdTime=2014-09-30, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84da40e602c, moduleTitle=华公司抗炎症药物secukinumab治疗银屑性关节炎取得重大突破, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=84da40e602c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1488550, encodeId=57e6148855060, content=<a href='/topic/show?id=0d5d16099ee' target=_blank style='color:#2F92EE;'>#Secukinumab#</a>, objectTitle=诺华旗下Secukinumab在银屑病临床研究中胜过依那西普, objectType=article, longId=21183, objectId=6dd7211832f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6dd7211832f, replyNumber=0, likeNumber=93, createdTime=2013-07-13, rootId=0, userName=朱睿睿, userId=a0b48435896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6dd7211832f, moduleTitle=诺华旗下Secukinumab在银屑病临床研究中胜过依那西普, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6dd7211832f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

Secukinumab

2020-05-29

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

Br J Dermatol：在体重≥90 kg的中重度斑块状银屑病患者中Secukinumab 的疗效如何？

2022-07-23

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

Rheumatol Ther：Secukinumab治疗银屑病关节炎或强直性脊柱炎患者的长期研究

2022-06-22

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

JAMA Dermatol：Secukinumab治疗与银屑病患者皮肌炎恶化的关系

2022-03-06

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

Clin Pharmacol Ther:Secukinumab治疗银屑病的创新儿科开发之路

2022-01-20

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

NEJM：Bimekizumab VS. Secukinumab 治疗斑块状银屑病的疗效及安全性

2021-10-13

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

SKYRIZI（risankizumab-rzaa）与COSENTYX（secukinumab）头对头研究：SKYRIZI优势显著

2020-06-16

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

Lancet：Secukinumab vs adalimumab用于治疗银屑病关节炎

2020-05-10

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

Lancet：Guselkumab vs Secukinumab用于中重度银屑病

2019-08-16

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

J Am Acad Dermatol：Secukinumab对中度到重度的头皮银屑病患者有效且安全

2017-08-14

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

Arthritis Rheumatol：苏金单抗Secukinumab治疗活动性类风湿关节炎研究

2017-06-05

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

2016NICE技术评估指南：Secukinumab用于非甾体类抗炎药或TNF抑制剂治疗后强直性脊柱炎活动期的治疗（TA407）发布

2016-10-28

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

2015NICE技术评估指南：secukinumab治疗中重度斑块型银屑病（TA350）发布

2016-10-27

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

NEJM：Secukinumab可显著改善活动期强直性脊柱炎症状

2015-12-25

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

诺华单抗secukinumab强直性脊柱炎III期临床大获成功

2014-10-29

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

华公司抗炎症药物secukinumab治疗银屑性关节炎取得重大突破

2014-09-30

朱睿睿 (审核中...)

前往app查看评论内容

#Secukinumab#

诺华旗下Secukinumab在银屑病临床研究中胜过依那西普

2013-07-13

科室
- - 订阅+
  - 更多科室
工具
服务